THE BARE LYMPHOCYTE SYNDROME AND THE REGULATION OF MHC EXPRESSION

The bare lymphocyte syndrome (BLS) is a hereditary immunodeficiency resulting from the absence of major istocompatibility complex class II (MHCII) expression. Considering the central role of MHCII molecules in the development and activation of CD4 + T cells, it is not surprising that the immune syst...

Full description

Saved in:
Bibliographic Details
Published inAnnual review of immunology Vol. 19; no. 1; pp. 331 - 373
Main Authors Reith, Walter, Mach, Bernard
Format Journal Article
LanguageEnglish
Published Palo Alto, CA 94303-0139 Annual Reviews 01.01.2001
4139 El Camino Way, P.O. Box 10139 Annual Reviews, Inc
USA
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The bare lymphocyte syndrome (BLS) is a hereditary immunodeficiency resulting from the absence of major istocompatibility complex class II (MHCII) expression. Considering the central role of MHCII molecules in the development and activation of CD4 + T cells, it is not surprising that the immune system of the patients is severely impaired. BLS is the prototype of a "disease of gene regulation." The affected genes encode RFXANK, RFX5, RFXAP, and CIITA, four regulatory factors that are highly specific and essential for MHCII genes. The first three are subunits of RFX, a trimeric complex that binds to all MHCII promoters. CIITA is a non-DNA-binding coactivator that functions as the master control factor for MHCII expression. The study of RFX and CIITA has made major contributions to our comprehension of the molecular mechanisms controlling MHCII genes and has made this system into a textbook model for the regulation of gene expression.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0732-0582
1545-3278
DOI:10.1146/annurev.immunol.19.1.331